THERAPY DOSSIER · th-26fc159171a2

Adeno-associated virus encoding the L1 cell adhesion molecule (AAV-L1) and chondroitinase ABC, alone and in combination

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22497349 ↗2012Reported benefit

Delayed applications of L1 and chondroitinase ABC promote recovery after spinal cord injury.

MouseSpinal cord injuryCompressionC57BL/6FemaleIntraspinal injectionDelayed injection 3 weeks after injury

Model: Thoracic compression spinal cord injury

All treatment groups showed enhanced locomotor recovery versus AAV-GFP. L1 overexpression improved voluntary movement without body weight support, chondroitinase ABC improved body weight support during stepping, and the combination improved both, correlating with increased cholinergic, GABAergic an…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…